Voruciclib, a selective inhibitor of CDK9, is a clinical stage drug candidate being evaluated in combination with standard therapy for the treatment of hematologic malignances and solid tumors.
ME-344, an inhibitor of mitochondrial oxidate phosphorylation (OXPHOS), is a clinical stage drug candidate being evaluated in combination with standard of care therapy for the treatment of solid tumors.